Search
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt was developed by The Medicines Company (acquired by Novartis). … It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
Propoxycaine
go.drugbank.com/drugs/DB09342ApprovedUsed in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].
Pramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIt was first approved by the FDA in 1997 [L5882]. … It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867].
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalIt works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]
Benzatropine
go.drugbank.com/drugs/DB00245ApprovedInvestigationalIt is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970.
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnFalk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalIt neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis.
Ketamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedIt was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.